HIGHLIGHTS
SUMMARY
The term "UCART19" used throughout this article refers to the S68587 cell product, first version of a second-generation allogeneic anti-CD19 CAR-T_cell therapy. Allogeneic CAR-T_cell therapies, in contrast, widen patient access to these innovative treatments through more easily scalable and readily available products with potentially reduced costs. To achieve these goals, genome-edited allogeneic T_cells from healthy donors should overcome two major issues: graft-versus-host disease (GVHD), which can be life threatening, and hostversus-graft rejection of HLA-incompatible CAR-T_cells, a major limiting tal CAR+ cells). Parameters such as . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.